Perceptive Advisors Lifts Solid Biosciences Stake to 11.2% with $0.001 Pre-Funded Warrants
SLDB has more than doubled off its 52-week low of $3.79.
Summary
Perceptive Advisors disclosed an 11.2% stake in Solid Biosciences, including 8.9 million pre-funded warrants exercisable at $0.001, though a 9.99% ownership cap currently prevents exercise.
Key Events · Ownership and Investor Activity · SLDB
-
Perceptive Stake Rises to 11.2%
Perceptive Advisors and Joseph Edelman report beneficial ownership of 12,046,579 shares, up from prior levels, representing 11.2% of Solid Biosciences' 107.4 million shares outstanding.
-
Pre-Funded Warrants Add Potential Upside
Perceptive Life Sciences Master Fund holds 8,912,655 pre-funded warrants exercisable at $0.001 per share, but a 9.99% beneficial ownership limitation currently blocks any exercise.
-
CIO Options Included in Stake
Adam Stone, Perceptive's CIO, holds 217,433 stock options, of which 139,933 are exercisable within 60 days, contributing to the aggregate ownership.
-
Institutional Conviction Builds
This filing follows RA Capital Management's 13D/A in June showing an 11.9% stake, indicating sustained institutional accumulation in Solid Biosciences.
Analysis · SLDB · Life Sciences
A major life sciences investor, Perceptive Advisors, now controls 11.2% of Solid Biosciences through 11.8 million shares and 8.9 million pre-funded warrants. The warrants are exercisable at $0.001 per share but are currently blocked by a 9.99% beneficial ownership cap, meaning Perceptive cannot convert them without exceeding the limit. This filing reveals a significant accumulation of potential voting power and economic interest, though the actual exercise is constrained. The stake increase follows a period of heavy insider and institutional buying, including RA Capital's 11.9% stake reported in June, suggesting strong conviction in the company's gene therapy pipeline despite recent losses.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.6% of the 1509 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLDB was trading at $9.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $986.5M. The 52-week trading range was $3.79 to $11.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.